key: cord-0748327-iamd515w
authors: Crombleholme, Timothy M.; Moise, Kenneth J.
title: Maternal Fetal Surgery During the COVID-19 Pandemic
date: 2020-05-18
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2020.100144
sha: 2ce4589579ff8e493a49e9cf5c43cbd0e12a1cd0
doc_id: 748327
cord_uid: iamd515w

nan

Clinical Guideline , "the lack of a predictable natural history, and therefore the uncertain 28 prognosis for TTTS , poses a significant challenge to the clinician caring for monochorionic 29 diamniotic twins" (3). As such, SMFM and other international organizations recommend serial 30 ultrasound every two weeks starting at 16 weeks gestation to delivery. Nonetheless, recent 31 recommendations have been proposed to decrease the frequency of ultrasound examinations in 32 pregnancy in an effort to limit the exposure of the health force as well as other patients to 33 frequency of ultrasounds in monochorionic twins to every four weeks in lieu of the usual two 35

week interval. 36

Most indications for fetal intervention should not fall under the prohibitions of elective 37 procedures during the COVID-19 pandemic. We would therefore suggest the following 38 considerations for maternal-fetal therapy during these unique times: 39

• Fetal centers should consider the use of telemedicine consultation prior to patient travel 40 to a distant site for treatment. 41

• COVID-19 testing capabilities currently vary widely across the country. In an optimal 42 situation, patients and any support person that plan to accompany them should be tested 43 for COVID-19 as proximate to the planned maternal-fetal procedure that will allow 44 sufficient time for the return of the result. 45

• Surveillance methods such as ultrasound surveillance for twin-twin transfusion every two 46 weeks should not be altered. 14 days. In this latter circumstance, undertaking the procedure prior to 26 weeks 74 gestation (criteria used in the MOMS trial) may not be possible. Extending the 75 gestational age window to 29 weeks gestation that has been reported in other fetal repair 76 series could be considered after review by a local ethics committee (6). 77

• In the fetal cases that might be candidates for an EXIT procedure (such as cervical 78 teratoma or lymphangioma) the procedure requires intubation with the use of 79 halogenated agents for uterine relaxation. After extensive counseling, an EXIT 80 procedure could be offered to a PUD or asymtompatic COVID-19 positive patient. In the 81 symptomatic COVID-19 positive patient, a better alternative to an EXIT procedure would be to plan a delivery by Cesarean section under regional anesthesia with an airway team 83 available in the operating suite for neonatal resuscitation. 84

As we have seen in most aspects of the healthcare response to the COVID-19 pandemic, a 85 coordinated, collaborative, national approach to help meet the patient's needs offers the best 86 hope of controlling the spread of the virus while still being able to meet the critical needs of 87 pregnant mothers in need of maternal-fetal intervention. Some fetal centers where the pandemic 88 has escalated have ceased offering maternal-fetal interventions. In these cases, consultation with 89 other fetal centers that continue to offer these procedures due to available resources should be 90 considered. We suggest these guidelines for consideration by Maternal-Fetal Surgery Centers to 91 achieve the goals of preserving resources to fight COVID-19, protect healthcare providers and 92 continue to provide life-saving and life-altering maternal-fetal interventions to the most 93 vulnerable of patients. 94 95

COVID-19: Recommendations for Management of Elective Surgical Procedures

MFM guidance for COVD-19

COVID-19 and treatment with NSAID's 109 and corticosteroids: shold we be limiting their use in a clinical setting? 110

Percutaneous fetoscopic closure of large open spina 113 bifida using a bilaminar skin substitute